Drug company executives were surprised by Trump's health policy nominees, such as vaccine skeptic Robert F. Kennedy Jr. and others with limited experience in healthcare. Concerns arose about potential impact on drug approvals, vaccine safety, and industry profits. Pharmaceutical officials seek to influence the new administration amidst uncertainty.